Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer

20091,018 citationsJournal Articlebronze Open Access

Authors

Michael Gnant · Medical University of Vienna

Brigitte Mlineritsch · Paracelsus Medical University

Walter Schippinger · Medical University of Graz

G. Luschin-Ebengreuth · Medical University of Graz

Sabine Pöstlberger · Sisters of Mercy of the Americas

Christian Menzel · Paracelsus Medical University

R. Jakesz

Abstract

The addition of zoledronic acid to adjuvant endocrine therapy improves disease-free survival in premenopausal patients with estrogen-responsive early breast cancer. (ClinicalTrials.gov number, NCT00295646.)

Topics & Keywords

Bone health and treatments Estrogen and related hormone effects Prostate Cancer Treatment and Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 360, Issue 7, pp. 679-691

DOI: 10.1056/nejmoa0806285

Field-Weighted Citation Impact: 79.28